Journal of Vaccine Research 2024, Vol.14, No.2, 40-53 http://medscipublisher.com/index.php/jvr 48 findings support the potential of IIV4 to offer broader protection against seasonal influenza compared to trivalent vaccines (Cadorna-Carlos et al., 2015). The ongoing phase III trials of these universal influenza vaccine candidates are expected to provide critical data on their efficacy and safety, paving the way for their potential approval and widespread use. 6 Challenges and Future Directions 6.1 Addressing antigenic diversity One of the primary challenges in developing a universal influenza vaccine is the antigenic diversity of the virus. Influenza viruses exhibit high genetic variability, particularly in the hemagglutinin (HA) and neuraminidase (NA) proteins, which are the main targets of current vaccines. This variability necessitates the annual reformulation of vaccines to match the predicted circulating strains, a process that is both time-consuming and often imperfect (Coughlan and Palese, 2018; Isakova-Sivak et al., 2021; Lo et al., 2021). The development of vaccines targeting highly conserved regions of the virus, such as the HA stalk or the matrix 2 (M2) protein, has shown promise in preclinical studies. These approaches aim to elicit broadly neutralizing antibodies that can provide cross-protection against diverse influenza strains (Pica and Palese, 2013; Zhao and Xu, 2018; Zhang et al., 2019). Despite these advancements, significant hurdles remain. The immune response to conserved antigens must be robust enough to confer protection against a wide array of influenza viruses, including those with pandemic potential. Recent studies have highlighted the importance of inducing a balanced immune response that includes both antibody and T-cell mediated immunity to achieve broad protection (Jang and Seong, 2019; Jang and Seong, 2020). Future research should focus on optimizing vaccine formulations to enhance the immunogenicity of conserved antigens and evaluating their efficacy in diverse populations through extensive clinical trials (Isakova-Sivak et al., 2021). 6.2 Overcoming technical and logistical barriers The production and distribution of universal influenza vaccines face several technical and logistical challenges. Traditional vaccine manufacturing methods, such as egg-based production, are not only time-consuming but also susceptible to issues like egg supply shortages and the risk of egg-adapted mutations that can reduce vaccine efficacy (Pica and Palese, 2013; Lo et al., 2021). Alternative production platforms, including cell-based and recombinant technologies, offer potential solutions by enabling faster and more scalable vaccine production. These methods also allow for the incorporation of novel antigens and adjuvants to enhance the breadth and durability of the immune response (Jang and Seong, 2019). Logistical challenges extend beyond production to include the distribution and administration of vaccines. Ensuring global access to universal influenza vaccines requires robust supply chains and infrastructure, particularly in low- and middle-income countries. Additionally, public health strategies must address vaccine hesitancy and ensure high vaccination coverage to achieve herd immunity (Coughlan and Palese, 2018; Jang and Seong, 2020). Future efforts should focus on developing cost-effective production methods, improving vaccine stability and storage, and implementing comprehensive vaccination programs that can rapidly respond to emerging influenza threats (Zhao and Xu, 2018; Zhang et al., 2019). 6.3 Future research directions Future research in the field of universal influenza vaccines should prioritize several key areas. First, there is a need for a deeper understanding of the immune correlates of protection. Identifying the specific immune responses that confer broad and long-lasting protection against influenza will guide the design of more effective vaccines (Jang and Seong, 2019; Isakova-Sivak et al., 2021). This includes studying the roles of different antibody isotypes, T-cell subsets, and innate immune responses in mediating protection (Pica and Palese, 2013; Jang and Seong, 2020). Second, the development of novel vaccine platforms and delivery methods should be explored. Mucosal vaccines, for example, have shown promise in eliciting strong local immune responses in the respiratory tract, which is the primary site of influenza infection (Coughlan and Palese, 2018; Lo et al., 2021). Additionally, prime-boost
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==